Clinical Trial Update: Phase 2 Study of IDH305 in Low Grade Gliomas [Phase 2]

View source ↗

Summary

Phase 2 study of IDH305 for low-grade gliomas has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• Low-grade Glioma

Drugs mentioned

• IDH305 (IDH305)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Glioma | Phase 2 | Status: WITHDRAWN